American Heart Journal
Volume 155, Issue 1 , Pages 19-25 , January 2008

Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)

  • Warren J. Cantor, MD

      Affiliations

    • Southlake Regional Health Centre, Newmarket, Ontario, Canada
    • University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Warren J. Cantor, MD, Southlake Regional Health Centre, 596 Davis Drive, Newmarket, Ontario, Canada L3Y 2P9.
    • ,
  • David Fitchett, MD

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada
    • Canadian Heart Research Centre, Toronto, Ontario, Canada
    • ,
  • Bjug Borgundvaag, MD

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • Mount Sinai Hospital, Toronto, Ontario, Canada
    • ,
  • Michael Heffernan, MD

      Affiliations

    • Halton Healthcare Services, Oakville, Ontario, Canada
    • ,
  • Eric A. Cohen, MD

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    • ,
  • Laurie J. Morrison, MD

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    • ,
  • Anatoly Langer, MD

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada
    • Canadian Heart Research Centre, Toronto, Ontario, Canada
    • ,
  • Shamir Mehta, MD

      Affiliations

    • McMaster University and Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
    • ,
  • Charles Lazzam, MD

      Affiliations

    • Trillium Health Centre, Mississauga, Ontario, Canada
    • ,
  • Brian Schwartz, MD

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    • ,
  • Vladimir Dzavik, MD

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • University Health Network, Toronto, Ontario, Canada
    • ,
  • Shaun G. Goodman, MD

      Affiliations

    • University of Toronto, Toronto, Ontario, Canada
    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada
    • Canadian Heart Research Centre, Toronto, Ontario, Canada

Received 1 June 2007 ,Accepted 27 August 2007.

References 

  1. Keeley EC, Boura J, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet. 2003;361:13–20
  2. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?. Am J Cardiol. 2003;92:824–826
  3. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941–2947
  4. Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 Analysis. Circulation. 2005;111:761–767
  5. Huynh T, O'Loughlin J, Joseph L, et al. Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study. CMAJ. 2006;175:1527–1532
  6. Cantor WJ, Brunet F, Ziegler CP, et al. Immediate angioplasty after thrombolysis: a systematic review. CMAJ. 2005;173:1473–1481
  7. Collet JP, Montalescot G, Le MM, et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 2006;48:1326–1335
  8. Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol. 2005;46:417–424
  9. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364:1045–1053
  10. Bednar F, Widimsky P, Krupicka J, et al. Interhospital transport for primary angioplasty improves the long-term outcome of acute myocardial infarction compared with immediate thrombolysis in the nearest hospital (one-year follow-up of the PRAGUE-1 study). Can J Cardiol. 2003;19:1133–1137
  11. di Mario C, Bolognese L, Maillard L, et al. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). Am Heart J. 2004;148:378–385
  12. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006;367:579–588
  13. Sinno MC, Khanal S, Al-Mallah MH, et al. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy–facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials. Am Heart J. 2007;153:579–586
  14. Cantor WJ, Choi R, Heffernan M, et al. Transfer for urgent percutaneous coronary intervention immediately after thrombolysis for ST elevation myocardial infarction: the Transfer-AMI Pilot Feasibility Study. Can J Cardiol. 2006;22:1121–1126
  15. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82–e292
  16. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135–142
  17. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators . Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–613
  18. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue–type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115:256–265
  19. The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  20. Dalby M, Bouzamondo A, Lechat P, et al. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809–1814
  21. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569–578
  22. Armstrong PW, WEST Steering Committee . A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J. 2006;27:1530–1538
  23. Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 2003;42:634–641
  24. Fernandez-Aviles F, Alonso JJ, Pena G, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J. 2007;28:949–960
  25. Coulter SA, Cannon CP, Ault KA, et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction : results from TIMI (Thrombolysis In Myocardial Infarction) 14. Circulation. 2000;101:2690–2695
  26. de Lemos JA, Morrow DA, Gibson CM, et al. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001;88:353–358
  27. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733–742
  28. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial—PRAGUE-2. Eur Heart J. 2003;24:94–104

 This study was supported by a grant from the Canadian Institutes of Health Research and an unrestricted grant from Hoffman La Roche, Canada.

 Dr Warren Cantor has received consulting fees, speaker's honoraria, and unrestricted research grants from Hoffman La Roche Canada and from Sanofi-Aventis.

 Dr Laurie Morrison has received speaker's honoraria from Hoffman La Roche and unrestricted research grants from Sanofi-Aventis.

 Dr Shaun Goodman has received consulting fees, speaker's honoraria, and research grants from Boehringer Ingelheim, Hoffmann La Roche, and Sanofi-Aventis.

 Dr Eric Cohen has received consulting fees and speaker's honoraria from Hoffman La Roche Canada and from Sanofi-Aventis.

 Dr David Fitchett has received consulting fees and speaker's honoraria from Hoffman La Roche, Bristol-Myers-Squibb, and Sanofi-Aventis.

 Dr David Fitchett has received consulting fees and speaker's honoraria from Hoffman La Roche, Bristol-Myers-Squibb, and Sanofi-Aventis

 Dr Bjug Borgundvaag has received consulting fees, speaker's honoraria and/or unrestricted research grants from Hoffman La Roche Canada, Sanofi-Aventis, and Key Pharmaceuticals.

 Dr Shamir Mehta has received consulting fees and/or speaker's honoraria and/or unrestricted research grants from Sanofi-Aventis, Bristol-Myers-Squibb, Astra Zeneca, Eli Lilly, Boston Scientific, GlaxoSmithKline, Oryx Pharmaceuticals, Abbott, Johnson and Johnson.

 Dr Michael Heffernan has received speaker's honoraria from Sanofi-Aventis.

 Dr Anatoly Langer has received consulting fees and/or speaker's honoraria and/or unrestricted research grants from Hoffman La Roche Canada, Astra Zeneca, Bayer, Biovail, BMS, Boston Scientific, Cordis (J&J), DuPont, Eli Lilly, Fournier, GlaxoSmithKline, Guidant, Medtronic, Merck Schering, Novartis, Oryx, Pfizer, Sanofi-Aventis, and Servier.

PII: S0002-8703(07)00711-9

doi: 10.1016/j.ahj.2007.08.025

American Heart Journal
Volume 155, Issue 1 , Pages 19-25 , January 2008

Article Tools

* Image Usage & Resolution